← All trials
NCT04365101
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2021
- First posted
- Apr 28, 2020
- Last posted
- May 19, 2020
- Enrollment
- 86
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Celularity, Inc.Lead sponsor
- Immune DesignCollaborator
- Immune DesignOverall official - principal investigator
- Lung Biotechnology PBCCollaborator
Drugs studied
Indications studied
- SARS-CoV-2
- Analgesics
- Anti-Infective Agents
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Coronaviridae Infections
- Immune System Diseases
- Immunologic Factors
- Lung Diseases
- Pneumonia
- Pneumonia, Viral
- Respiratory Tract Diseases
- Respiratory Tract Infections
- RNA Virus Infections
- Virus Diseases
- Coronavirus
- Coronavirus Infections
- Nidovirales Infections
- Severe Acute Respiratory Syndrome
- Physiological Effects of Drugs
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.